Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte to consolidate two of its lines of shares

Thu, 13th May 2021 11:22

(Sharecast News) - Cell engineering company MaxCyte announced the consolidation of two of its lines of common stock into a single unrestricted line of common stock on Thursday.
The AIM-traded firm said it would be effected by the transfer of all stock comprising the Regulation S restricted trading line 'MXCL', to the unrestricted common stock trading line 'MXCT'.

It had previously said it intended the two lines of common stock to be consolidated following expiration of the distribution compliance period in relation to new shares on 22 May 2020.

The consolidation was intended to help both trading liquidity and transparency for shareholders, and would result in the cancellation of trading of the Regulation S restricted trading line 'MXCL'.

Currently, MaxCyte common stock is held as unrestricted stock trading under the symbol 'MXCT', and restricted stock trading under the symbols 'MXCL' and 'MXCN'.

The number of unrestricted shares of common stock trading under 'MXCT' is 74,454,534, while there are 9,900,089 restricted shares under 'MXCL' and 330,000 restricted shares under 'MXCN'.

"The consolidation will have a record date of 21 May and will be effective from 24 May, following which 84,354,623 MaxCyte common stock will be held as unrestricted shares in 'MXCT'," the board said in its statement.

"The number of restricted shares of common stock trading under the symbol MXCN will remain as 330,000 for the remainder of the applicable distribution compliance period."

At 1104 BST, shares in MaxCyte were up 0.06% at 892.5p.
More News
8 May 2019 15:58

MaxCyte begins dosing second cohort in MCY-M11 clinical trial

(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.

Read more
8 May 2019 12:11

MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial

LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a

Read more
24 Apr 2019 11:37

MaxCyte Outlook Confident As Loss Narrows In 2018 On Higher Revenue

LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a

Read more
17 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 18 April UnileverQ1 ResultsPZ CussonsTrading SolutionsTrading 19 events

Read more
8 Apr 2019 13:58

MaxCyte Launches ExPERT Cellular Engineering Technology Platform

LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced

Read more
8 Apr 2019 08:34

MaxCyte launches new generation of cellular engineering instruments

(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.

Read more
1 Mar 2019 10:05

MaxCyte Inks Multi-Drug Clinical And Commercial Agreement With Kite

LONDON (Alliance News) - Biotechnology company MaxCyte Inc on Friday said it has expanded its business relationship with Kite by signing a multi-drug clinical and commercial agreement.Under

Read more
5 Feb 2019 17:45

UPDATE: MaxCyte Placing Fully Subscribed; Raises Over GBP10.0 Million (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it has raised GBP10.0 million from a placing of 5.9 million shares at 170 pence each.The life sciences company placed 5.9 million just

Read more
5 Feb 2019 10:22

MaxCyte To Raise At Least GBP10 Million For Future Growth Plans (ALLISS)

LONDON (Alliance News) - MaxCyte Inc on Tuesday said it plans to raise at least GBP10 million via a placing of shares in order to accelerate its growth strategy.The life sciences company no

Read more
15 Jan 2019 11:18

MaxCyte Guides For Revenue Growth And Earnings Above Expectations

LONDON (Alliance News) - MaxCyte Inc on Tuesday guided for a 19% increase in its 2018 revenue with the firm expecting its annual earnings to exceed market views.The life science company in

Read more
24 Oct 2018 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 25 OctoberGreen & Smart WoodsAlumasc GroupFriday 26 OctoberArgos Capital

Read more
10 Oct 2018 11:47

MaxCyte Begins Patient Trial Of Proposed Cancer Treatment MCY-M11

LONDON (Alliance News) - Life sciences and medicines company MaxCyte Inc on Wednesday said it has dosed the first patient in its phase I trial for MCY-M11.MCY-M11 is a mesothelin targeting

Read more
24 Sep 2018 10:18

MaxCyte Interim Revenue Rises But Loss Widens On CARMA Development

LONDON (Alliance News) - MaxCyte Inc on Monday said its loss widened in the first half of 2018 as it continued to invest in the development of its CARMA drug platform.The life sciences said

Read more
17 Sep 2018 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 18 September Ocado GroupTrading Statement DP PolandHalf Year Year Year Year

Read more
26 Jul 2018 17:50

DIRECTOR DEALINGS: Wife Of MaxCyte Non-Executive Director Buys Shares

LONDON (Alliance News) - Medical & technology company MaxCyte Inc said that Karin Johnston, wife of Non-Executive Director John Johnston, purchased 11,500 shares at a price of 240 pence per on

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.